376 related articles for article (PubMed ID: 15196057)
1. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
Brinkmann V; Cyster JG; Hla T
Am J Transplant; 2004 Jul; 4(7):1019-25. PubMed ID: 15196057
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
3. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A; Igarashi Y
Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
5. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
6. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.
Sarai K; Shikata K; Shikata Y; Omori K; Watanabe N; Sasaki M; Nishishita S; Wada J; Goda N; Kataoka N; Makino H
Am J Physiol Cell Physiol; 2009 Oct; 297(4):C945-54. PubMed ID: 19657053
[TBL] [Abstract][Full Text] [Related]
7. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
8. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
Cyster JG; Schwab SR
Annu Rev Immunol; 2012; 30():69-94. PubMed ID: 22149932
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
Matloubian M; Lo CG; Cinamon G; Lesneski MJ; Xu Y; Brinkmann V; Allende ML; Proia RL; Cyster JG
Nature; 2004 Jan; 427(6972):355-60. PubMed ID: 14737169
[TBL] [Abstract][Full Text] [Related]
11. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
12. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
14. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
[TBL] [Abstract][Full Text] [Related]
15. [Effects of sphingosine 1-phosphate on functions of T cell - review].
Huang WR; Wang LS; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
[TBL] [Abstract][Full Text] [Related]
16. FTY720: mechanism of action and potential benefit in organ transplantation.
Brinkmann V
Yonsei Med J; 2004 Dec; 45(6):991-7. PubMed ID: 15627289
[TBL] [Abstract][Full Text] [Related]
17. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
[TBL] [Abstract][Full Text] [Related]
19. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.
Stone ML; Sharma AK; Zhao Y; Charles EJ; Huerter ME; Johnston WF; Kron IL; Lynch KR; Laubach VE
Am J Physiol Lung Cell Mol Physiol; 2015 Jun; 308(12):L1245-52. PubMed ID: 25910934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
